To be an AgentDasatinib monohydrate
Target Country: France Germany Switzerland
Post Date: 2016-11-23
Valid to: 2017-04-10
Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). If there is any manufacturer need to sell this product in European countries, please contact me.